表紙
市場調查報告書

亞太地區的糖尿病治療藥市場 - 成長率,趨勢,預測(2019年∼2024年)

Asia-Pacific Diabetes Care Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 808269
出版日期 內容資訊 英文 90 Pages
商品交期: 2-3個工作天內
價格
亞太地區的糖尿病治療藥市場 - 成長率,趨勢,預測(2019年∼2024年) Asia-Pacific Diabetes Care Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 90 Pages
簡介

亞太地區的糖尿病治療藥市場,預計從2019年到2024年間,將以4.82%的年複合成長率發展,成長到2019年238億美元的規模。

本報告提供亞太地區的糖尿病治療藥市場調查,市場概要,各治療藥類型、各國市場規模的變化與預測,市場成長要素及阻礙因素分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 市場分析:各治療藥類型
    • 口服藥
    • 胰島素
    • 胰島素以外的注射藥
    • 多劑聯合治療
  • 市場分析:各地區
    • 亞太地區
      • 澳洲
      • 中國
      • 印度
      • 印尼
      • 日本
      • 馬來西亞
      • 菲律賓
      • 韓國
      • 泰國
      • 越南

第6章 市場指標

  • 第一型糖尿病人口(實在數值、預測值)
  • 第二型糖尿病人口(實在數值、預測值)

第7章 競爭情形

  • 企業簡介
    • 武田藥品工業
    • Pfizer
    • Eli Lilly
    • Janssen Pharmaceuticals
    • Astellas Pharma Inc.
    • Boehringer Ingelheim
    • Merck And Co.
    • AstraZeneca
    • Bristol Myers Squibb
    • Novartis
    • Sanofi

第8章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 62942

Market Overview

The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.

Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population.

The Asian population gets diabetes at a younger age in comparison to the Western population. The reason for this early diabetes development is the sudden change in lifestyle, due to rapid economic growth.

Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia.

Scope of the Report

The Asia-Pacific diabetes drugs report covered by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by countries.

Key Market Trends - Oral Anti-Diabetes Drugs Take 67% of the Asia-Pacific Diabetes Drugs Market.

The use of oral anti-diabetes drugs is rising, due to the fact that new generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.

SGLT-2 and GLP-1 are linked to lowering the mortality rate more effectively than DPP-4 inhibitors.

Meglitinide and sulfonylureas are oral hypoglycemic drugs that directly arouse the discharge of insulin from pancreatic beta cells. They hold a significant market share, of 14.27% and 9.62%, respectively, in the Asia-Pacific anti-diabetics drugs market.

China and Japan Occupy more than a 50% Share in the Asia-Pacific Diabetes Drugs Market.

In the Asia-Pacific region, China and Japan have recognized as potential developing markets, due to the growing diabetic population in this region.

Japan is a mature market, with some associated challenges, like slow economic growth, the aging population, and increased competition. One particular challenge in this region is the growing preference for oral anti-diabetics among type-2 diabetic patients, thereby, leading to a negative insulin volume development.

China has the highest market share and is expected to grow with a steady CAGR of 4%. It also contributes 15% to the global diabetes drugs market.

The country is witnessing a significant increase in the number of generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.

Competitive Landscape

The Asia-Pacific diabetes care drugs market is highly fragmented, with a few major manufacturers gaining presence in major countries of the Asia-Pacific market, while the remaining market comprises other local or region-specific manufacturers.

Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as driving innovations, helping the diabetes drugs market to increase in the Asia-Pacific region. For instance, Biocon has launched its insulin glargine biosimilar, in Japan and Malaysia, partnering with local manufacturers for further commercialization.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug
    • 5.1.1 Oral Anti-diabetic Drugs
      • 5.1.1.1 Biguanides (Value and Volume 2012-2024)
      • 5.1.1.1.1 Metformin
      • 5.1.1.2 Alpha - Glucosidase Inhibitors (Value and Volume 2012-2024)
      • 5.1.1.2.1 Alpha - Glucosidase Inhibitors
      • 5.1.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
      • 5.1.1.3.1 Bromocriptin (Cycloset)
      • 5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
      • 5.1.1.4.1 Invokana (Canagliflozin)
      • 5.1.1.4.2 Jardiance (Empagliflozin)
      • 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
      • 5.1.1.4.4 Suglat (Ipragliflozin)
      • 5.1.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
      • 5.1.1.5.1 Januvia (Sitagliptin)
      • 5.1.1.5.2 Onglyza (Saxagliptin)
      • 5.1.1.5.3 Tradjenta (Linagliptin)
      • 5.1.1.5.4 Vipidia/Nesina (Alogliptin)
      • 5.1.1.5.5 Galvus (Vildagliptin)
      • 5.1.1.6 Sulfonylureas (Value and Volume 2012-2024)
      • 5.1.1.6.1 Sulfonylureas
      • 5.1.1.7 Meglitinides (Value and Volume 2012-2024)
      • 5.1.1.7.1 Meglitinides
    • 5.1.2 Insulin
      • 5.1.2.1 Basal or Long-acting Insulins
      • 5.1.2.1.1 Lantus (Insulin Glargine)
      • 5.1.2.1.2 Levemir (Insulin Detemir)
      • 5.1.2.1.3 Toujeo (Insulin Glargine)
      • 5.1.2.1.4 Tresiba (Insulin Degludec)
      • 5.1.2.1.5 Basaglar (Insulin Glargine)
      • 5.1.2.2 Bolus or Fast-acting Insulins
      • 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
      • 5.1.2.2.2 Humalog (Insulin Lispro)
      • 5.1.2.2.3 Apidra (Insulin Glulisine)
      • 5.1.2.3 Traditional Human Insulins
      • 5.1.2.3.1 Novolin/Actrapid/Insulatard
      • 5.1.2.3.2 Humilin
      • 5.1.2.3.3 Insuman
      • 5.1.2.4 Biosimilar Insulins
      • 5.1.2.4.1 Insulin Glargine Biosimilars
      • 5.1.2.4.2 Human Insulin Biosimilars
    • 5.1.3 Non-insulin Injectable Drugs
      • 5.1.3.1 GLP-1 Receptor Agonists
      • 5.1.3.1.1 Victoza (Liraglutide)
      • 5.1.3.1.2 Byetta (Exenatide)
      • 5.1.3.1.3 Bydureon (Exenatide)
      • 5.1.3.1.4 Trulicity (Dulaglutide)
      • 5.1.3.1.5 Lyxumia (Lixisenatide)
      • 5.1.3.2 Amylin Analogue
      • 5.1.3.2.1 Symlin (Pramlintide)
    • 5.1.4 Combination Drugs
      • 5.1.4.1 Insulin Combinations
      • 5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
      • 5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
      • 5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
      • 5.1.4.2 Oral Combination
      • 5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
  • 5.2 Geography
    • 5.2.1 Asia-Pacific
      • 5.2.1.1 Australia (Value and Volume 2012-2024)
      • 5.2.1.1.1 Oral Anti-diabetic Drugs
      • 5.2.1.1.2 Insulin
      • 5.2.1.1.3 Non-Insulin Injectable Drugs
      • 5.2.1.1.4 Combination Drugs
      • 5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.2 China (Value and Volume 2012-2024)
      • 5.2.1.2.1 Oral Anti-diabetic Drugs
      • 5.2.1.2.2 Insulin
      • 5.2.1.2.3 Non-Insulin Injectable Drugs
      • 5.2.1.2.4 Combination Drugs
      • 5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.3 India (Value and Volume 2012-2024)
      • 5.2.1.3.1 Oral Anti-diabetic Drugs
      • 5.2.1.3.2 Insulin
      • 5.2.1.3.3 Non-Insulin Injectable Drugs
      • 5.2.1.3.4 Combination Drugs
      • 5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.4 Indonesia (Value and Volume 2012-2024)
      • 5.2.1.4.1 Oral Anti-diabetic Drugs
      • 5.2.1.4.2 Insulin
      • 5.2.1.4.3 Non-Insulin Injectable Drugs
      • 5.2.1.4.4 Combination Drugs
      • 5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.5 Japan (Value and Volume 2012-2024)
      • 5.2.1.5.1 Oral Anti-diabetic Drugs
      • 5.2.1.5.2 Insulin
      • 5.2.1.5.3 Non-Insulin Injectable Drugs
      • 5.2.1.5.4 Combination Drugs
      • 5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.6 Malaysia (Value and Volume 2012-2024)
      • 5.2.1.6.1 Oral Anti-diabetic Drugs
      • 5.2.1.6.2 Insulin
      • 5.2.1.6.3 Non-Insulin Injectable Drugs
      • 5.2.1.6.4 Combination Drugs
      • 5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.7 Philippines (Value and Volume 2012-2024)
      • 5.2.1.7.1 Oral Anti-diabetic Drugs
      • 5.2.1.7.2 Insulin
      • 5.2.1.7.3 Non-Insulin Injectable Drugs
      • 5.2.1.7.4 Combination Drugs
      • 5.2.1.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.8 South Korea (Value and Volume 2012-2024)
      • 5.2.1.8.1 Oral Anti-diabetic Drugs
      • 5.2.1.8.2 Insulin
      • 5.2.1.8.3 Non-Insulin Injectable Drugs
      • 5.2.1.8.4 Combination Drugs
      • 5.2.1.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.9 Thailand (Value and Volume 2012-2024)
      • 5.2.1.9.1 Oral Anti-diabetic Drugs
      • 5.2.1.9.2 Insulin
      • 5.2.1.9.3 Non-Insulin Injectable Drugs
      • 5.2.1.9.4 Combination Drugs
      • 5.2.1.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.10 Vietnam (Value and Volume 2012-2024)
      • 5.2.1.10.1 Oral Anti-diabetic Drugs
      • 5.2.1.10.2 Insulin
      • 5.2.1.10.3 Non-Insulin Injectable Drugs
      • 5.2.1.10.4 Combination Drugs
      • 5.2.1.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
      • 5.2.1.11 Rest of Asia Pacific (Value and Volume 2012-2024)
      • 5.2.1.11.1 Oral Anti-diabetic Drugs
      • 5.2.1.11.2 Insulin
      • 5.2.1.11.3 Non-Insulin Injectable Drugs
      • 5.2.1.11.4 Combination Drugs
      • 5.2.1.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

6 MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population (2012-2024)
  • 6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Takeda
    • 7.1.2 Pfizer
    • 7.1.3 Eli Lilly
    • 7.1.4 Janssen Pharmaceuticals
    • 7.1.5 Astellas
    • 7.1.6 Boehringer Ingelheim
    • 7.1.7 Merck And Co.
    • 7.1.8 AstraZeneca
    • 7.1.9 Bristol Myers Squibb
    • 7.1.10 Novartis
    • 7.1.11 Sanofi

8 MARKET OPPORTUNITIES AND FUTURE TRENDS